EGFR
All Product Categories
-
EGFR Inhibitors
(578)
View all products
-
EGFR Agonist
(1)
View all products
-
EGFR Antagonist
(1)
View all products
-
EGFR Activators
(5)
View all products
-
EGFR Modulators
(6)
View all products
-
EGFR Chemicals
(3)
View all products
-
EGFR Inducers
(3)
View all products
-
EGFR Degraders
(22)
View all products
-
EGFR Controls
(6)
View all products
-
EGFR Substrate
(1)
View all products
-
EGFR Ligands
(13)
View all products
-
EGFR Related Products (746)
Related Products (746)
-
N-Methyl-dosimertinib-d5
0 ImagesCat. No.: HY-142283CSCAS No.: 2719690-98-7N-Methyl-dosimertinib-d5 is the deuterium labeled of N-Methyl-dosimertinib.
-
EGFR-IN-88
0 ImagesCat. No.: HY-156033CAS No.: 2944452-34-8
-
HW12
0 ImagesCat. No.: HY-P11781CAS No.: 875142-27-1HW12 is a scrambled peptide control with no EGFR ligand activity. HW12 shows low cellular uptake levels in EGFR-positive cells. HW12 exerts weak growth inhibitory effects on pancreatic cancer. HW12 serves as a scrambled peptide control for EGFR-targeted GE11 (HY-P10128)-conjugated mixed micelles. HW12 can be used in pancreatic cancer research.
-
rel-Lifirafenib
0 ImagesCat. No.: HY-18957ACAS No.: 1446090-77-2Synonyms: rel-BGB-283rel-Lifirafenib (rel-BGB-283) is the relative configuration of Lifirafenib (HY-18957). Lifirafenib is a potent Raf Kinase and EGFR inhibitor.
-
Pred17
0 ImagesCat. No.: HY-169346Pred17 is a potent EGFR inhibitor. Pred17 has the potential for the research of lung cancer.
-
EGFR T790M/L858R-IN-7
0 ImagesCat. No.: HY-158178CAS No.: 3032760-90-7EGFR T790M/L858R-IN-7 (Compound 72) is a novel pyrimidine compound that inhibits the EGFR T790M and L858R mutation with a high efficacy (93% inhibition rate at 0.05 μM). EGFR T790M/L858R-IN-7 functions by specifically binding to the kinase domain of EGFR, thereby inhibiting its phosphorylation activity.
-
REGN-1400
0 ImagesCat. No.: HY-P991244REGN-1400 is a humanized monoclonal antibody inhibitor targeting ErbB3. REGN-1400 reduces tumor cell proliferation by inhibiting ErbB3 and blocking related signaling pathways. REGN-1400 is promising for research of solid tumors such as non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and squamous cell carcinoma of the head and neck (SCCHN) .
-
HER2-IN-7
0 ImagesCat. No.: HY-143874CAS No.: 2387574-01-6HER2-IN-7 is a potent inhibitor of HER2. Deregulation of ErbB family signalling modulates proliferation, invasion, metastasis, angiogenesis, and tumour cell survival. HER2-IN-7 has the potential for the research of diseases associated ErbBs (especially HER2), including cancer (extracted from patent WO2019214634A1, compound 23).
-
AZ5385
0 ImagesCat. No.: HY-163377CAS No.: 848439-89-4AZ5385 is an EGFR-tyrosine kinase inhibitor. AZ5385 is a HRV-2 virus blocker, with EC50 of 0.35 µM. AZ5385 affects the late stage of viral life cycle.
-
BPIQ-I
0 ImagesCat. No.: HY-112405CAS No.: 174709-30-9Synonyms: PD 159121BPIQ-I (PD 159121) is a potent and ATP-competitive EGFR tyrosine kinase inhibitor.. BPIQ-I shows anti-proliferative actively.
-
EGFR-IN-101
0 ImagesCat. No.: HY-161269CAS No.: 2982583-44-6EGFR-IN-101 (I-10) is a 2-phenylamino pyrimidine derivative. EGFR-IN-101 is a EGFR inhibitor. The IC50 values for EGFRL858R/T790M/C797S and Ba/F3-EGFRL858R/T790M/C797S are 33.26 and 106.4 nM, respectively. EGFR-IN-101 can be used IN the study of non-small cell lung cancer (NSCLC).
-
O-Desmethyl dacomitinib
0 ImagesCat. No.: HY-160828CAS No.: 2468202-15-3Synonyms: PF-05199265O-Desmethyl dacomitinib (PF-05199265) is the major circulating metabolite of dacomitinib (HY-13272) and acts as a pan-epidermal growth factor receptor (ErbB) tyrosine kinase inhibitor. O-Desmethyl dacomitinib exhibits a much lower exposure level than dacomitinib in the body. O-Desmethyl dacomitinib is highly dependent on the enzymatic activity of CYP2D6 for its formation.
-
Afatinib dimaleate (Standard)
0 ImagesSynonyms: BIBW 2992MA2 (Standard)Afatinib (dimaleate) (Standard) is the analytical standard of Afatinib (dimaleate). This product is intended for research and analytical applications. Afatinib (BIBW 2992) dimaleate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib dimaleate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer.
-
NSC114126
0 ImagesCat. No.: HY-144445CAS No.: 24909-18-0
-
EGFR-IN-180
0 ImagesCat. No.: HY-178824CAS No.: 1454651-67-2EGFR-IN-180 (Compound L15) is an EGFR inhibitor. EGFR-IN-180 shows inhibitory activity against EFGR and EGFR harboring the L858R/T790M/C797S triple drug-resistant mutation, with IC50 values of 80.96 nM and 16.43 nM, reapectively. EGFR-IN-180 can be used for the study of non-small cell lung cancer (NSCLC).
-
Lapatinib-13C,d7
0 ImagesCat. No.: HY-50898S5CAS No.: 1210608-87-9Synonyms: GW572016-13C,d7; GW2016-13C,d7
-
EGFR ligand-19
0 ImagesCat. No.: HY-189361CAS No.: 3017179-42-6
